Shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 5, 2009, Pages 967-972

  Han, Yuchi ^a   Peters, Dana C ^a   Dokhan, Basem ^b   Manning, Warren J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

Cardiovascular magnetic resonance imaging; Dilated cardiomyopathy; Late gadolinium enhancement; Optimal inversion time

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC VALUE; FEMALE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHANTOM; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

AGED; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 70350460729     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21953     Document Type: Article

References (23)

1. [No authors listed.] Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
2. [No authors listed.] Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-2007.
3. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651-1658. (Pubitemid 32479962)
4. Rubin R, Strayer D, Rubin E, McDonald J. Rubin's pathology: clinicopathologic foundations of medicine. Philadelphia: Lippincott Williams & Wilkins; 2008.
5. Rossi MA. Patterns of myocardial fibrosis in idiopathic cardiomyopathies and chronic Chagasic cardiopathy. Can J Cardiol 1991; 7:287-294.
6. Mahon NG, Madden BP, Caforio AL, et al. Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 39:455-462.
7. Zimmermann O, Grebe O, Merkle N, et al. Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail 2006;8: 162-166. (Pubitemid 43240850)
8. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-1985. (Pubitemid 44738448)
9. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:2414-2421. (Pubitemid 351826874)
10. Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002;39:1055-1060.
11. Look D, Locker D. Time savings in measure of NMR and EPR relaxation times. Rev Sci Instrum 1970;41:250-251.
12. Henkelman RM. Measurement of signal intensities in the presence of noise in MR images. Med Phys 1985;12:232-233. (Pubitemid 15089010)
13. Klein C, Nekolla SG, Balbach T, et al. The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging 2004;20: 588-593. (Pubitemid 39313734)
14. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-59.
15. Vohringer M, Mahrholdt H, Yilmaz A, Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 2007;32:129-137. (Pubitemid 46980389)
16. Bohl S, Wassmuth R, Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 2008;24:597-607.
17. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
18. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-1453. (Pubitemid 30832880)
19. Fieno DS, Kim RJ, Chen EL, et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000;36:1985-1991.
20. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105: 224-229.
21. Jerosch-Herold M, Sheridan DC, Kushner JD, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;295: H1234-H1242.
22. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52:1574-1580.
23. Maron S, Appelbaum E, Harrigan C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;1:184-191.